Lataa...
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
AIM: The aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations. METHODS: Eligible adults with advanced malignancies for which no furth...
Tallennettuna:
| Julkaisussa: | Br J Clin Pharmacol |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5089614/ https://ncbi.nlm.nih.gov/pubmed/27121262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12991 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|